Panelists discuss how, for a patient who has an aggressive disease, physicians will plan for monthly serum markers including serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE); if they start seeing an increase in the disease, they plan an imaging for bone marrow biopsy and consider a diagnostics lumbar puncture.
Daniel Kim, MD, MBA discusses how genomic testing has revolutionized patient selection for active surveillance by integrating molecular insights that transcend traditional clinical parameters, enabling more nuanced risk stratification and personalized management of intermediate-risk prostate cancer.
Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
In closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.
Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Christina Henson, MD, spoke about the impact negative trial results can have on advancing the head and neck cancer field forward.
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.
Experts weigh in on the practical applications of PSMA PET imaging
In this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
CancerNetwork® sat down with C. Jillian Tsai, MD, PhD, at the 2021 American Society for Radiation Oncology to talk about the use of stereotactic body radiation therapy to treat breast and lung cancer.
Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.
The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.
KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how results of a study aimed at determining pathological complete response in patients with locally advanced breast cancer by cell-free DNA may spare certain patients from needing further biopsies.